Final Program

SUNDAY • MAY 15 115
2:15 What’s in E-cigarettes and Are They Safe?: Pulmonary
Biomarkers and Harmful Pulmonary Pathological Consequences
N. Benowitz, MD, San Francisco, CA
2:35 What’s Inhaled by Vaping? Dosimetry, Deposition, Distribution,
and Topography: Pulmonary Physiological and Clinical Effects
R. Robinson, PhD, Rochester, NY
2:55 Basic and Translational Science of E-Cigarette with Flavoring
Agents: In Vitro and In Vivo Pulmonary Effects
I. Rahman, PhD, Rochester, NY
3:15 Mucosal Immune Responses to E-Cigarette Exposures:
Preclinical and Clinical Models
I. Jaspers, PhD, Chapel Hill, NC
3:35 Electronic Cigarette Use and Harm Reversal in Clinic: Users’
Perspectives
R. Polosa, MD, PhD, Catania, Italy
3:55 E-Cigarettes and Public Health: Pulmonary Clinical Data on
Behavioral, Perception, Addiction Vs. Cessation Tools of
E-Cigarettes and Flavorings
J.M. Samet, MD, MS, Los Angeles, CA
A88
BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
COMMUNITY ACQUIRED PNEUMONIA IN THE
ELDERLY PATIENT
Assemblies on Microbiology, Tuberculosis and Pulmonary Infections;
Allergy, Immunology and Inflammation; Behavioral Science and Health
Services Research; Clinical Problems; Critical Care; Nursing;
Respiratory Cell and Molecular Biology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 3016/3018 (West Building, Level 3)
Target Audience
Health care providers, at all levels of training, who are caring for patients with
pneumonia; clinical researchers, translational and bench investigators.
Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings regarding alterations associated with aging that affect
host response to lung infections and effectiveness of vaccines;
• identify risk factors for and implement strategies to prevent pneumonia in
elderly patients;
• implement appropriate management of pneumonia.
Pneumonia is a leading cause of mortality globally. As the population is aging,
the incidence of pneumonia is increasing, related to alterations in host defense
as a consequence of aging and cellular senescence, and also the concomitant
greater burden of comorbidities and polypharmacy in older patients. This
translational session will discuss bench investigations elucidating mechanisms
impacting host defense to lung infection and host immune responses to
vaccines in older adults. Clinically oriented presentations will consider the
syndrome of aspiration pneumonia and the impact of comorbidities and
medications on risk for community acquired pneumonia. Talks will also address
management and prevention of pneumonia in elderly patients.
Chairing: K.A. Crothers, MD, Seattle, WA
C.M. Luna, MD, PhD, Buenos Aires, Argentina
E.R. Neptune, MD, Baltimore, MD
2:15 Aging and Host Defense in Pneumonia
E.R. Neptune, MD, Baltimore, MD
2:35 Importance of Comorbidities on Risk for Pneumonia in an
Aging Population
M.I. Restrepo, MD, MSc, San Antonio, TX
2:55 Aspiration Pneumonia: A Distinct Pneumonia Phenotype?
M.J. Lanspa, MD, MS, Salt Lake City, UT
3:15 Tailoring Management of Pneumonia to the Elderly Patient
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom
3:35 Immunosenescence and Vaccination
C. Weyand, MD, PhD, Stanford, CA
3:55 Pneumonia Prevention
M.S. Niederman, MD, New York, NY
A89
There will be a 5-minute discussion after each talk.
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
FROM BEAUTY TO BREAKING BAD: UNCOVERING
THE WORLD OF DRUG INDUCED PULMONARY
HYPERTENSION
Assembly on Pulmonary Circulation
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)
Target Audience
Pulmonary and critical care physicians, nurse practitioners, social workers,
researchers in pulmonary vascular biology, addiction specialists and trainees
who care for patients with pulmonary hypertension.
Objectives
At the conclusion of this session, the participant will be able to:
• diagnose drug related pulmonary vascular toxicity;
• learn new findings about the mechanism and pathobiology of drug induced
pulmonary hypertension;
• relate recent clinical and basic findings to future scientific environment and
patient exposures.
Timed to the 50th anniversary of the European Aminorex epidemic, the goal of this
symposium is to highlight the impact of therapeutics and illicit drugs in causing
pulmonary vascular disease and bring awareness to a disease sub-phenotype
which is often less focused on. This session will start with a broad historical
perspective on known and recently discovered drug induced PH entities, move
quickly to pathobiology and mechanisms underlying the clinical disorder, and
identify novel phenotypes associated with prescribed and illicit drugs. The session
will then advance onto the discussion of aberrancies in drug metabolism and the
unique role of the pulmonary vasculature in this process. The session will
conclude with a perspective from regulatory agencies (US-FDA) on post-approval
drug safety monitoring and the concept of pharmacovigilance.
SUNDAY AFTERNOON
ATS 2016 • San Francisco